Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn’s disease
| Autor: | Veena Logarajah, Fang Kuan Chiou, Christina Ong, Maria Janelle Liwanag, Ajmal Kader, Yuqin Cher, Bi Xia Ang, Poh Ting Lim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Crohn’s disease medicine.medical_specialty Adolescent Azathioprine Southeast asian Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Enteral Nutrition Maintenance therapy Crohn Disease Internal medicine Medicine Humans lcsh:RC799-869 Child Thiopurines Retrospective Studies Crohn's disease Singapore Exclusive enteral nutrition medicine.diagnostic_test Thiopurine methyltransferase biology business.industry Remission Induction Gastroenterology Retrospective cohort study General Medicine medicine.disease Combined Modality Therapy Paediatric 030220 oncology & carcinogenesis Erythrocyte sedimentation rate Child Preschool Cohort biology.protein 030211 gastroenterology & hepatology Female lcsh:Diseases of the digestive system. Gastroenterology business Immunosuppressive Agents medicine.drug Research Article |
| Zdroj: | BMC Gastroenterology, Vol 18, Iss 1, Pp 1-9 (2018) BMC Gastroenterology |
| Popis: | Background Exclusive enteral nutrition (EEN) is as effective as corticosteroids in inducing remission in children with Crohn’s disease (CD). However, over 50% of these children relapse by 12 months of diagnosis. Thiopurines are commonly prescribed as maintenance therapy for CD, but evidence for its efficacy is controversial. Data on the effectiveness of EEN in Southeast Asian (SEA) children with CD is scarce. This study aims to evaluate the efficacy of EEN induction therapy in a cohort of SEA children with newly diagnosed CD. The secondary aim was to evaluate concomitant early azathioprine (EAZ) use in determining remission rate at 6 and 12 months. Methods Case records of all children with newly diagnosed CD from 2011 to 2014 were reviewed and relevant demographic as well as clinical data were extracted. The primary outcome measure was the number of patients who completed EEN induction therapy and achieved remission (Paediatric Crohn’s Disease Activity Index; PCDAI≤10). Factors influencing duration of remission were evaluated in particular early azathioprine (EAZ) defined as starting azathioprine within one month of diagnosis versus late azathioprine (LAZ) use. Results Forty children with newly diagnosed CD were identified. Thirty-three children: 67% boys, median age 13y (range 3–17) completed 8 weeks of EEN induction therapy and 91% achieved remission. Significant improvements were seen in PCDAI scores (32.7 ± 9.2 to 4.2 ± 5.1; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|